Skip to content
6-K

Foreign Interim / Material

NYMOX PHARMACEUTICAL CORPORATION NYMXF

0001640334-23-002155

← back to feed
Filed
Nov 15, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Current Liabilities Q3 2023 · Sep 30, 2023 $2.57M
Current Liabilities Q3 2023 · Dec 31, 2022 $2.11M
Total Liabilities Q3 2023 · Sep 30, 2023 $2.57M
Total Liabilities Q3 2023 · Dec 31, 2022 $2.11M
Current Assets Q3 2023 · Sep 30, 2023 $654K
Current Assets Q3 2023 · Dec 31, 2022 $1.46M
Total Assets Q3 2023 · Sep 30, 2023 $669K
Total Assets Q3 2023 · Dec 31, 2022 $1.63M
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$3.96M
Stockholders Equity Q3 2023 · Sep 30, 2022 $773K
Stockholders Equity Q3 2023 · Dec 31, 2021 −$506K
Rd Expense Q3 2023 · Sep 30, 2022 $892K
Rd Expense Q3 2023 · Sep 30, 2022 $6.04M
Net Income Q3 2023 · Sep 30, 2022 −$5.24M
Cost Of Revenue Q3 2023 · Sep 30, 2022 $0
Cost Of Revenue Q3 2023 · Sep 30, 2022 $0
Revenue Q3 2023 · Sep 30, 2022 $0
Revenue restated Q3 2023 · Sep 30, 2022 $5K